Practical Evidence-Based Recommendations for Patients with Multiple Sclerosis Who Want to Have Children

被引：0

作者：

Yara Dadalti Fragoso

Tarso Adoni

Joseph B. Bidin Brooks

Alessandro Finkelsztejn

Paulo Diniz da Gama

Anderson K. Grzesiuk

Vanessa Daccach Marques

Monica Fiuza K. Parolin

Henry K. Sato

Daniel Lima Varela

Claudia Cristina F. Vasconcelos

机构：

[1] Universidade Metropolitana de Santos,

[2] Hospital Sirio-Libanes de Sao Paulo,undefined

[3] Hospital de Clinicas de Porto Alegre,undefined

[4] Pontificia Universidade Católica Campus Sorocaba,undefined

[5] Neurologic Clinic in Cuiaba,undefined

[6] Universidade de Sao Paulo Campus Ribeirao Preto,undefined

[7] Neurologic Clinic in Curitiba,undefined

[8] Instituto de Neurologia de Curitiba,undefined

[9] Servico de Neurologia e Neurocirurgia,undefined

[10] Universidade Federal do Estado do Rio de Janeiro,undefined

来源：

Neurology and Therapy | 2018年 / 7卷

关键词：

Family planning; Multiple sclerosis; Neurology; Pregnancy; Therapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Multiple sclerosis (MS) management presently aims to reach a state of no (or minimal) evidence of disease activity. The development and commercialization of new drugs has led to a renewed interest in family planning, since patients with MS may face a future with reduced (or no) disease-related neurological disability. The advice of neurologists is often sought by patients who want to have children and need to know more about disease control at conception and during pregnancy and the puerperium. When MS is well controlled, the simple withdrawal of drugs for patients who intend to conceive is not an option. On the other hand, not all treatments presently recommended for MS are considered safe during conception, pregnancy and/or breastfeeding. The objective of the present study was to summarize the practical and evidence-based recommendations for family planning when our patients (women and men) have MS.

引用

页码：207 / 232

页数：25

共 495 条

[81] Huang SM(2018)An update on the use of disease-modifying therapy in pregnant patients with multiple sclerosis CNS Drugs 71 826-806
[82] Gupta R(2017)Evaluating the safety of medication exposures during pregnancy: a case study of study designs and data sources in multiple sclerosis Drugs Real World Outcomes 4 e377-811
[83] Portaccio E(2013)Is it correct for a woman with multiple sclerosis to forgo medication because she may become pregnant? Arq Neuropsiquiatr 131 336-1253
[84] Ghezzi A(2017)Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis Mult Scler 22 1506-430
[85] Hakiki B(2017)Dramatic rebounds of MS during pregnancy following fingolimod withdrawal Neurol Neuroimmunol Neuroinflamm 3 279-1802
[86] Pakpoor J(2015)Natalizumab discontinuation and disease restart in pregnancy: a case series Acta Neurol Scand 20 e109-809
[87] Disanto G(2016)Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning Mult Scler 9 174-1042
[88] Lacey MV(2014)Pseudotumoral rebound of multiple sclerosis in a pregnant patient after stopping natalizumab Mult Scler Relat Disord 9 363-125
[89] Holla-Bhar R(2013)Rebound of disease activity during pregnancy after withdrawal of fingolimod Eur J Neurol 68 S8-348
[90] Iellamo A(2018)Therapeutic inertia in the new landscape of multiple sclerosis care Front Neurol 37 1232-1359

← 4 5 6 7 8 9 10 11 12 13 →